Ania K. Knap, PhD
Ania is a life-sciences entrepreneur and consultant with more than 21 years of experience in pharmaceutical R&D. She is a Partner and co-founder of New England PharmAssociates, LLC.
In 2004, she co-founded MaxThera, Inc, a pharmaceutical research company developing novel antibacterial agents to treat life-threatening infections caused by antibiotic resistant pathogens. She served as President and Chief Scientific Officer of the company. MaxThera was formed through acquisition of the drug discovery portfolio Ania had developed as head of discovery research at Genome Therapeutics. The company was funded initially by the US BioShield Program and SBIR grants administered through the NIAID (NIH). MaxThera’s antibacterial assets were sold in 2010 to Biota Holdings Limited, a Melbourne Australia anti-infectives company.
Prior to starting MaxThera, Ania was Sr. Director of Discovery Research at Genome Therapeutics, a role she took on following a her role as Head of Enzymology at Kinetix, In Cambridge, MA, where her expertise in kinase enzymology played a key role in preparing the company for its acquisition by Amgen. Prior to joining Kinetix she was Director of Biology at RiboGene, an anti-infectives company in Hayward, CA and a Project Team Leader in inflammation and cardiovascular therapeutics at Novartis (formerly Ciba-Geigy).